TC Biopharm Stock (NASDAQ:TCBP)
Previous Close
$1.31
52W Range
$1.12 - $1.14K
50D Avg
$4.98
200D Avg
$9.81
Market Cap
$444.12K
Avg Vol (3M)
$678.31K
Beta
0.11
Div Yield
-
TCBP Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TCBP Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
BDRX | Biodexa Pharmaceuticals Plc |
VIRI | Virios Therapeutics, Inc. |
ICU | SeaStar Medical Holding Corporation |
BWV | Onconetix, Inc. |
PXMD | PaxMedica, Inc. Common Stock |
PHIO | Phio Pharmaceuticals Corp. |
REVB | Revelation Biosciences, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
RNAZ | TransCode Therapeutics, Inc. |
HILS | Tharimmune, Inc. |
VRAX | Virax Biolabs Group Limited |
ALLR | Allarity Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
SONN | Sonnet BioTherapeutics Holdings, Inc. |
UNCY | Unicycive Therapeutics, Inc. |
ZURA | Zura Bio Limited |
PALI | Palisade Bio, Inc. |